Skip to main content
ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., Friedberg, J., Hodgson, D. C., Schwartz, C. L., Wilder, R. B., Wilson, L. D., Yunes, M. J. 2011; 8 (5): 302-308


Combined-modality therapy, consisting of chemotherapy followed by radiation therapy (RT), represents the standard of care for most patients with unfavorable-prognosis early-stage Hodgkin's lymphoma. The most widely accepted chemotherapy regimen is ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine); however, recent trials have evaluated other regimens such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and Stanford V. After chemotherapy, the standard radiation field is involved-field RT, although there is increasing interest now in involved-node RT. The authors review recent trials on chemotherapy and RT for unfavorable-prognosis early-stage Hodgkin's lymphoma. This article presents illustrative clinical cases, with treatment recommendations from an expert panel of radiation oncologists and medical oncologists.

View details for DOI 10.1016/j.jacr.2011.01.009

View details for Web of Science ID 000306201300006

View details for PubMedID 21531305